ICON plc has announced that, as part of its planned succession of executive leadership, Mr. Ciaran Murray will transition to the role of Chairman of the Board of Directors and Dr. Steve Cutler will be appointed as Chief Executive Officer, with both changes effective as of 1st March 2017.
Dr. Cutler joined ICON in 2011 as President, ICON Clinical Research Services. He was promoted to ICON plc Chief Operating Officer in January 2014 and was appointed to the Board of Directors in November 2015. “Steve will bring significant industry experience and proven leadership capabilities to the role of Chief Executive Officer,” said Mr. Declan McKeon, acting Chairman of the Board. “As Chief Operating Officer, Steve has strengthened and expanded our global operations and he is well placed to lead the company to continued growth and success. The Board is happy to have such a strong internal successor to take over from Ciaran now that he has decided to transition to the role of chairman.”
Commenting on his appointment Dr. Cutler added, “I am pleased and excited to be appointed as ICON’s Chief Executive Officer. I look forward to continuing to work with Ciaran and the rest of the Board during the transition period and beyond. ICON has a strong management team and together we will remain focused on enhancing our position as the CRO partner of choice in drug development. Also, I would like to personally thank Ciaran for his leadership of ICON over the last five years.”
Prior to joining ICON, Dr. Cutler was Chief Executive Officer of Kendle. Prior to Kendle, Dr. Cutler held various senior roles in both Quintiles and Sandoz (now Novartis). Dr. Cutler holds a B.Sc. and a Ph.D from the University of Sydney and a Masters of Business Administration from the University of Birmingham (UK).
Mr. McKeon also thanked Mr. Murray for his leadership of the company. “Since 2011, Ciaran has led ICON through a transformative phase of our development which has seen the company deliver outstanding financial and operational performance and broaden its strategic capabilities. Ciaran has also been an excellent partner for the Board and we are delighted that he has accepted our offer to transition to the role of Chairman of the Board of Directors.”
Mr. Murray commented, “The last five years as ICON’s CEO have been the most exciting and fulfilling of my professional career. Since I took over as Chief Executive Officer, five years ago the company has made significant progress. Through our focus on innovation, investment in talent and by continuing to enhance and broaden our service capabilities we have driven significant growth and shareholder value. During this time, we have developed a strong management team and with ICON well positioned for the future the time is right for me to step down as Chief Executive Officer and for Steve to take over leadership of ICON. I look forward to continuing to work with Steve and the rest of the Board in my new role as Chairman.”
Source: ICON
Novartis will acquire Mariana’s lead candidate MC-339, a radioligand therapy (RLT) designed to target small-cell lung cancer. Last year, Mariana had raised $175m in a Series B round from several funds and pharma giant Eli Lilly.
The company’s aspiration to expand the use of its obesity products to cardiovascular indications has been successful. In March, its blockbuster drug Wegovy was approved by the US Food and Drug Administration (FDA) for reducing the risk of cardiovascular diseases in obese or overweight adults.
Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space.
